Skip to content

Ionis Pharmaceuticals IONS Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$92.53M+59.7%-$229.39M-78.4%-$128.61M-204%$123.55M+184%-$146.94M-40.8%
$3.3M+1.3%$3.26M+44.5%$2.26M-0.5%$2.27M+1.7%$2.23M-0.5%
$43.28M-0.1%$43.32M+39.1%$31.15M+4.9%$29.69M-0.1%$29.72M-17.8%
$218K+171%-$308K-245%$213K+1,165%-$20K-117%$116K-96.7%
$2.35M+19.4%$1.97M+19.1%$1.65M+0.4%$1.65M+0.2%$1.64M-1.9%
-$338K$0-100%$2.14M-84.2%$13.48M+1,434%-$1.01M-120%
-$3.1M-$8.81M-$25.97M-174%
$7.39M$100.95M+893%$10.17M-17.8%$12.37M-30.1%
$21M$84.15M+2,528%$3.2M+862%$333K+102%
$7.63M-88.7%$67.58M+342%-$27.97M-317%$12.87M+125%-$52.48M
-$20.82M-8.8%-$19.13M-18.7%-$16.11M+22.4%-$20.77M-51.4%-$13.72M+4.1%
$161K-93.8%$2.61M+12,960%$20K$0-100%$92K+1,414%
$40K-99.1%$4.63M+217%-$3.94M-1,769%$236K+287%$61K-97.0%
$22.58M+2,766%$788K-97.4%$29.91M+263%-$18.31M-746%-$2.16M+15.7%
$3.49M+1.2%$3.44M+112%$1.63M-37.2%$2.59M+0.1%$2.59M+0.7%
-$792.82M-476%-$137.71M-4.8%-$131.44M-187%$151.34M+200%-$150.78M-29.8%
$21.76M+2.2%$21.29M+304%$5.27M-57.2%$12.31M-2.2%$12.58M-50.7%
$192.76M-75.7%$791.97M+144%$323.94M-34.1%$491.59M+58.0%$311.07M-6.8%
$752.82M+90.5%$395.12M-6.4%$422.21M+9.4%$385.79M-22.0%$494.76M+15.1%
$1.49M+8.9%$1.37M-17.8%$1.66M-15.5%$1.96M+202%$651K-74.4%
$19.6M
$228.9M0.0%$228.9M0.0%$228.9M0.0%$228.9M+1.6%
$536.82M+228%-$419.51M-559%$91.34M+176%-$120.07M-170%$170.46M
$57.3M$0+100%-$3.53M-374%$1.29M-42.6%$2.24M+8,200%
$57.26M-90.3%$591.18M+628%$81.22M+6,413%$1.25M-43.3%$2.2M
-$138K$595K+156%$232K+148%
-$198.88M-686%$33.92M-17.3%$41.04M+23.9%$33.11M+49.7%$22.12M+124%
$90K-98.3%$5.38M+2,810%$185K-96.4%$5.12M+5,467%$92K-98.2%
-$8K-$278K-$400K+94.8%
$6.19M+9.1%$5.67M+11.5%$5.09M-13.4%$5.87M-17.4%$7.11M-24.8%
$43.28M-0.1%$43.32M+39.1%$31.15M+4.9%$29.69M-0.1%$29.72M-17.8%
$2.35M+19.4%$1.97M+19.1%$1.65M+0.4%$1.65M+0.2%$1.64M-1.9%
$661K+3.6%$638K+2.7%$621K+3.8%$598K+2.7%$582K+26.8%
$3.3M+1.3%$3.26M+44.5%$2.26M-0.5%$2.27M+1.7%$2.23M-0.5%
$22.58M+2,766%$788K-97.4%$29.91M+263%-$18.31M-746%-$2.16M+15.7%
$7.63M-$27.97M-$52.48M
$669.75K0.0%$669.75K0.0%$669.75K0.0%$669.75K+227%
$21M$84.15M+2,528%$3.2M+862%$333K+102%
-$80.19M-235%$59.22M-$43.04M-248%
$7.39M$100.95M+893%$10.17M-17.8%$12.37M-30.1%
$4.09M0.0%$4.09M0.0%$4.09M0.0%$4.09M
$3.49M+1.2%$3.44M+112%$1.63M-37.2%$2.59M+0.1%$2.59M+0.7%
$22.58M$0-100%$29.91M+261%-$18.62M-907%-$1.85M+28.1%
$1.49M+8.9%$1.37M-17.8%$1.66M-15.5%$1.96M+202%$651K-74.4%
$752.82M+90.5%$395.12M-6.4%$422.21M+9.4%$385.79M-22.0%$494.76M+15.1%
$19.6M
$57.3M-46.9%$107.82M+32.7%$81.26M+6,214%$1.29M-42.6%$2.24M+457%
$44K-15.4%$52K+26.8%$41K+2.5%$40K-4.8%$42K+2.4%
$19.6M0.0%$19.6M0.0%$19.6M0.0%$19.6M-52.8%
$2.98M-62.5%$7.96M+240%$2.34M-43.7%$4.15M+184%$1.46M-61.8%
$363.52M-13.0%$417.79M+31.8%$316.9M+1.5%$312.23M+12.1%$278.47M-17.5%
$446.5K0.0%$446.5K0.0%$446.5K0.0%$446.5K+129%
$645K0.0%$645K0.0%$645K0.0%$645K+404%
$2.65M0.0%$2.65M0.0%$2.65M0.0%$2.65M+23.3%
21%
-5.1%
-0.1%
-4.7%
-$95.3M0.0%-$95.3M0.0%-$95.3M0.0%-$95.3M+17.3%
$394.75K0.0%$394.75K0.0%$394.75K0.0%$394.75K+145%
$5.16M+6.9%$4.83M+14.6%$4.21M+2.4%$4.11M+0.1%$4.11M-2.0%
1+300%0.30.0%0.30.0%0.30.0%0.3
-$138K$0+100%-$82K-114%$595K+156%$232K+148%
$203.33M
$0$0$0$0-100%
$1.79M0.0%$1.79M0.0%$1.79M0.0%$1.79M+96.2%
$34.25K0.0%$34.25K0.0%$34.25K0.0%$34.25K-98.2%
$11.5K0.0%$11.5K0.0%$11.5K0.0%$11.5K
-$162K0.0%-$162K0.0%-$162K0.0%-$162K
-$8K-$278K-$400K+94.8%
-$814.58M-412%-$159M-16.3%-$136.71M-$163.35M-15.3%
-$814.58M-412%-$159M-16.3%-$136.71M-$163.35M-15.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Ionis Pharmaceuticals generate?
Ionis Pharmaceuticals (IONS) generated -$910.6M in operating cash flow over the trailing twelve months.
What is Ionis Pharmaceuticals's free cash flow?
After $60.6M of capital expenditures, Ionis Pharmaceuticals's free cash flow was -$1.3B over the trailing twelve months, down 133.2% year over year.
Where does Ionis Pharmaceuticals's cash flow data come from?
Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.